BioCentury | May 28, 2020
Product Development

May 27 Quick Takes: EC approves Zeposia in RRMS; plus Dupixent approved in children, La Jolla, Shionogi, Alnylam and Bold

EC approves Zeposia ozanimod for relapsing-remitting MS The European Commission approved Zeposia ozanimod from Bristol Myers Squibb Co. (NYSE:BMY) to treat relapsing-remitting multiple sclerosis (RRMS). FDA approved the S1P receptor modulator in March for relapsing...
BioCentury | Apr 3, 2020
Distillery Therapeutics

Depletion of the mitochondrial chaperone HspA9 for BRAF-mutant melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Reducing production of the mitochondrial chaperone HspA9 could treat BRAF-mutant melanoma. In melanoma patients, high tumor levels of HspA9 mRNA were associated with poor survival. In two human melanoma cell...
BioCentury | Oct 25, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Inflammatory bowel disease (IBD) In vitro and mouse studies identified an isopropylcarboxamide-based Hsp90B1 inhibitor that could help treat ulcerative colitis (UC). Structure-based design, chemical synthesis and in vitro activity and binding assays of isopropylcarboxamide...
BioCentury | Mar 7, 2018
Distillery Therapeutics

Cancer

INDICATION: Solid tumors In vitro and cell culture studies identified Hsp90B1 inhibitors that could help treat solid tumors. Chemical synthesis, in vitro binding and cell-based assays of resorcinol analogs yielded a compound that inhibited Hsp90B1...
BioCentury | Nov 3, 2017
Strategy

Broadening Novartis’ NET

...PSMA-R2, which targets prostate-specific membrane antigen (PSMA; FOLH1; GCPII); and 68Ga-NeoBOMB1, a gastrin-releasing peptide receptor (GRP-R...
BioCentury | Oct 13, 2017
Financial News

Intezyne raises $10M in series A

On Oct. 6, Intezyne Technologies Inc. (Tampa, Fla.) raised $10 million in an oversubscribed series A round led by existing investor Gaston Capital Healthcare Fund (GCHF). Undisclosed high-net-worth investors and family offices also participated. CFO...
BioCentury | Oct 6, 2017
Financial News

Intezyne raises $10M series A

Intezyne Technologies Inc. (Tampa, Fla.) raised $10 million in an oversubscribed series A round led by existing investor Gaston Capital Healthcare Fund (GCHF). Undisclosed high-net-worth investors and family offices also participated. CFO E. Russell McAllister...
BioCentury | Aug 17, 2017
Targets & Mechanisms

GRP-THINK AT THE BBB

Biogen Inc. has discovered antibodies in patients with a rare CNS autoimmune disease that could provide a new way to deliver mAbs across the blood-brain barrier, an application with wide-reaching ramifications for neurologic drug development....
BioCentury | Jun 22, 2017
Translation in Brief

TERS talk

A UCSD group has added "transmissible ER stress (TERS)" to the list of cancer's survival strategies. In a study published this month in Science Signaling , the group showed cancer cells undergoing ER stress send soluble...
BioCentury | Jun 14, 2017
Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Mouse studies suggest inhibiting HspA5 could help treat pancreatic ductal adenocarcinoma (PDAC). In male and female mouse models of PDAC, HspA5 knockdown decreased number of ducts with acinar-to-ductal metaplasia, Pancreatic Intraepithelial Neoplasias...
Items per page:
1 - 10 of 64